Varra F, Varras M, Varra V, Theodosis-Nobelos P
Mol Med Rep. 2024; 29(6).
PMID: 38606791
PMC: 11025031.
DOI: 10.3892/mmr.2024.13219.
Cinar A, Kupeli Cinar A, Guclu H
Int Ophthalmol. 2024; 44(1):31.
PMID: 38329554
DOI: 10.1007/s10792-024-02947-8.
Kaymak H, Munk M, Tedford S, Croissant C, Tedford C, Ruckert R
Clin Ophthalmol. 2023; 17:3549-3559.
PMID: 38026594
PMC: 10676639.
DOI: 10.2147/OPTH.S415883.
Azagew A, Yohanes Y, Beko Z, Ferede Y, Mekonnen C
PLoS One. 2023; 18(6):e0286627.
PMID: 37289766
PMC: 10249865.
DOI: 10.1371/journal.pone.0286627.
Baillif S, Staccini P, Weber M, Delyfer M, Le Mer Y, Gualino V
Pharmaceutics. 2022; 14(11).
PMID: 36365209
PMC: 9693281.
DOI: 10.3390/pharmaceutics14112391.
A Cross-Sectional Study of Various Imaging and Biochemical Biomarkers in Patients with Diabetic Macular Edema in Different Stages of Diabetic Retinopathy.
Naveen P, Sahu V, Pathak M
Clin Ophthalmol. 2022; 16:3129-3134.
PMID: 36176978
PMC: 9514258.
DOI: 10.2147/OPTH.S377956.
Comparison of intravitreal aflibercept and dexamethasone implant in the treatment of macular edema associated with diabetic retinopathy or retinal vein occlusion: a Meta-analysis and systematic review.
Qiu X, Hu X, Qin Y, Ma J, Liu Q, Qin L
Int J Ophthalmol. 2022; 15(9):1511-1519.
PMID: 36124196
PMC: 9453398.
DOI: 10.18240/ijo.2022.09.15.
Evaluation of the Effect of Garlic Tablet as a Complementary Treatment for Patients with Diabetic Retinopathy.
Afarid M, Sadeghi E, Johari M, Namvar E, Sanie-Jahromi F
J Diabetes Res. 2022; 2022:6620661.
PMID: 35875346
PMC: 9303161.
DOI: 10.1155/2022/6620661.
Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study.
Khoramnia R, Peto T, Koch F, Taylor S, de Sousa J, Hill L
Br J Ophthalmol. 2022; 107(10):1502-1508.
PMID: 35840291
PMC: 10579189.
DOI: 10.1136/bjo-2022-321415.
Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study.
Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A
Pharmaceutics. 2022; 14(4).
PMID: 35456557
PMC: 9025285.
DOI: 10.3390/pharmaceutics14040723.
Diabetic Macular Edema Detection Using End-to-End Deep Fusion Model and Anatomical Landmark Visualization on an Edge Computing Device.
Wang T, Chen Y, Chen J, Liu J, Wu P, Chang S
Front Med (Lausanne). 2022; 9:851644.
PMID: 35445051
PMC: 9014123.
DOI: 10.3389/fmed.2022.851644.
Correlation of Volume of Macular Edema with Retinal Tomography Features in Diabetic Retinopathy Eyes.
Gadde S, Kshirsagar A, Anegondi N, Mochi T, Heymans S, Ghosh A
J Pers Med. 2021; 11(12).
PMID: 34945810
PMC: 8708057.
DOI: 10.3390/jpm11121337.
Diagnostic performance of deep-learning-based screening methods for diabetic retinopathy in primary care-A meta-analysis.
Wewetzer L, Held L, Steinhauser J
PLoS One. 2021; 16(8):e0255034.
PMID: 34375355
PMC: 8354436.
DOI: 10.1371/journal.pone.0255034.
Health Economic and Safety Considerations for Artificial Intelligence Applications in Diabetic Retinopathy Screening.
Xie Y, Gunasekeran D, Balaskas K, Keane P, Sim D, Bachmann L
Transl Vis Sci Technol. 2020; 9(2):22.
PMID: 32818083
PMC: 7396187.
DOI: 10.1167/tvst.9.2.22.
Vitrectomy with internal limiting membrane peeling versus nonsurgical treatment for diabetic macular edema with massive hard exudates.
Lin H, Yang C, Chen S, Hsieh Y
PLoS One. 2020; 15(7):e0236867.
PMID: 32735583
PMC: 7394381.
DOI: 10.1371/journal.pone.0236867.
Cell Atlas of The Human Fovea and Peripheral Retina.
Yan W, Peng Y, Van Zyl T, Regev A, Shekhar K, Juric D
Sci Rep. 2020; 10(1):9802.
PMID: 32555229
PMC: 7299956.
DOI: 10.1038/s41598-020-66092-9.
Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema.
Byun M, Osher J, Riemann C
BMJ Open Ophthalmol. 2020; 5(1):e000416.
PMID: 32518834
PMC: 7254114.
DOI: 10.1136/bmjophth-2019-000416.
A New Approach for Diabetic Macular Edema Treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes.
Estebainha R, Goldhardt R, Falcao M
Curr Ophthalmol Rep. 2020; 8(1):1-10.
PMID: 32346496
PMC: 7188023.
DOI: 10.1007/s40135-020-00225-1.
Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE.
Elbarky A
Clin Ophthalmol. 2020; 14:823-830.
PMID: 32214793
PMC: 7083643.
DOI: 10.2147/OPTH.S238740.
Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.
Bhatwadekar A, Kansara V, Ciulla T
Expert Opin Investig Drugs. 2020; 29(3):237-244.
PMID: 31985300
PMC: 7265898.
DOI: 10.1080/13543784.2020.1723078.